PRESS RELEASE published on 09/16/2026 at 07:30, 1 month 16 days ago Inside Information / Other news releases Sensorion announces submission of draft registration statement to SEC for potential U.S. IPO. Company focuses on novel therapies for hearing loss disorders SEC Sensorion Hearing Loss Therapies Draft Registration Statement U.S. IPO
BRIEF published on 09/15/2026 at 07:35, 1 month 17 days ago Sensorion Completes Reverse Share Split Biotechnology Shareholder Compensation Reverse Share Split Hearing Loss Therapies Euronext Growth Market
PRESS RELEASE published on 09/15/2026 at 07:30, 1 month 17 days ago Inside Information / Other news releases Sensorion completes reverse share split, exchanging 50 existing shares for 1 new share with €5 par value. New shares listed on Euronext Growth market in Paris under ISIN code FR001401A9Z0 Shareholder Compensation ISIN Code Reverse Share Split Sensorion Euronext Growth Market
BRIEF published on 09/03/2026 at 07:35, 1 month 29 days ago Sensorion receives authorization to initiate a clinical trial in France Gene Therapy Clinical Trial France Hearing Sensory
BRIEF published on 09/03/2026 at 07:35, 1 month 29 days ago Sensorion Receives Approval for SENS-601 Trial in France Gene Therapy Clinical Trial Sensorion Hearing Loss SENS-601
PRESS RELEASE published on 09/03/2026 at 07:30, 1 month 29 days ago Inside Information / Other news releases Sensorion receives approval from ANSM to start Phase I/II clinical trial of SENS-601, a gene therapy for GJB2-related hearing loss in France. Event hosted to discuss program details Gene Therapy Clinical Trial Sensorion SENS-601 GJB2-related Hearing Loss
BRIEF published on 06/10/2026 at 07:35, 4 months 22 days ago Sensorion Advances SENS-601 for GJB2-Related Hearing Loss Clinical Trials Gene Therapy Sensorion SENS-601 GJB2 Hearing Loss
BRIEF published on 06/10/2026 at 07:35, 4 months 22 days ago Sensorion Refocuses on SENS-601 for Gene Therapy Clinical Trials Gene Therapy Sensorion Hearing Loss SENS-601
PRESS RELEASE published on 06/10/2026 at 07:30, 4 months 22 days ago Inside Information / Other news releases Sensorion achieves key regulatory milestones for SENS-601 addressing GJB2-related hearing loss and discontinues SENS-501. Fast Track procedure granted by ANSM in France. Clinical trials planned in Canada and U.S. IND submission targeted by 2026 Clinical Trials Gene Therapy Sensorion Regulatory Milestones GJB2-related Hearing Loss
BRIEF published on 05/18/2026 at 07:35, 5 months 15 days ago Sensorion Appoints Fred Chereau as CEO Biotechnology CEO Appointment Gene Therapy Sensorion Fred Chereau
Published on 11/02/2026 at 14:00, 59 minutes ago GameSquare to Report Q3 2026 Financial Results on November 16, 2026
Published on 11/02/2026 at 14:00, 59 minutes ago Tectonic Metals Intersects 5.61 g/t Au Over 41.15 m, Including 12.94 g/t Au Over 13.72 m, Within 2.86 g/t Au Over 91.44 m, Strengthening Evidence for a Second Gold System at the Flat Gold Project
Published on 11/02/2026 at 13:30, 1 hour 29 minutes ago Electric Metals (USA) Limited Announces Results of Annual Meeting of Stockholders
Published on 11/02/2026 at 13:30, 1 hour 29 minutes ago Predictiv AI Awarded Metrolinx Master Agreement for On-Demand Transit Software and Related Services
Published on 11/02/2026 at 13:00, 1 hour 59 minutes ago International Battery Metals Announces Second Quarter Fiscal 2027 Financial Results Conference Call and Webcast
Published on 11/02/2026 at 14:35, 24 minutes ago Bitmine Immersion Technologies (BMNR) Announces ETH Holdings Reach 6.06 Million Tokens, and Total Crypto and Total Cash & Marketable Securities Holdings of $14.5 Billion
Published on 11/02/2026 at 14:25, 34 minutes ago Cell Impact to evaluate NC titanium for undisclosed customers
Published on 11/02/2026 at 14:05, 54 minutes ago Infiterra democratizes subscription commerce for MSPs and IT distributors
Published on 11/02/2026 at 14:00, 59 minutes ago 2G Energy AG announces long-planned change to its Management Board
Published on 10/30/2026 at 23:00, 2 days 15 hours ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 18:00, 2 days 20 hours ago 2026 half-year earnings & third quarter revenue
Published on 10/30/2026 at 12:00, 3 days 2 hours ago Capital increase through exercise of subscription rights
